CLINICAL_TRIALS ClinicalTrials.gov record update

PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03709680
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:58.873788+00:00
Published At: 2025-01-14T00:00:00+00:00
Record Updated At: 2025-01-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ewing Sarcoma", "Solid Tumors", "Rhabdoid Tumor", "Rhabdomyosarcoma", "Neuroblastoma", "Medulloblastoma", "Diffuse Intrinsic Pontine Glioma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-01-14"
protocolSection.identificationModule.nctId: "NCT03709680"
protocolSection.identificationModule.officialTitle: "PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE\u00ae) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.